The NOD-like receptor protein 3 (NLRP3) inflammasome activated by calcific crystals is particularly relevant to the initiation and progression of calcific tendinopathy. Moreover, NLRP3 inflammasome–driven inflammation controlled at low-grade levels could promote collagen regeneration of the tendon. Recently, it has been reported that glyburide, a hypoglycemic drug, inhibits the NLRP3 inflammasome, a possible diagnostic biomarker and therapeutic target for calcific tendinopathy.
Study Design:
Controlled laboratory study.
Purpose:
To investigate whether glyburide has therapeutic effects on calcific tendinopathy and to determine the role of the NLRP3 inflammasome in such an effect.
Methods:
A total of 60 Sprague-Dawley rats underwent collagenase injection into the Achilles tendon to induce calcific tendinopathy. Sixteen weeks later, the rats were randomly assigned to 3 groups: (1) 10% dimethyl sulfoxide (DMSO) group, (2) celecoxib group, and (3) glyburide group. Gross morphological and histological analyses were conducted to evaluate tendon healing. Additionally, real-time quantitative polymerase chain reaction and Western blotting were performed to assess whether glyburide degeneration influences the expression of components of the NLRP3 inflammasome, including NLRP3, apoptosis-associated speckle-like protein (ASC), caspase-1, IL-1β, and IL-18, within Achilles tendon enthesis at 2 weeks after treatment.
Results:
The Achilles tendon tissues in the glyburide group exhibited significantly less degeneration and fewer calcium deposits compared with the celecoxib and DMSO groups. The mRNA and protein expression levels of NLRP3, ASC, caspase-1, IL-1β, and IL-18 were reduced in the glyburide group compared with both the celecoxib and DMSO groups.
Conclusion:
Glyburide targets the upstream NLRP3 signaling pathway, potentially accelerating tendon healing, which may contribute to advancements in the treatment of calcific tendinopathy.
Clinical Relevance:
Glyburide acts as an NLRP3 inflammasome inhibitor and may be a new option for tendon healing in calcific tendinopathy.
BowlerMARaddatzMAJohnsonCLLindmanBRMerrymanWD.Celecoxib is associated with dystrophic calcification and aortic valve stenosis. JACC Basic Transl Sci. 2019;4(2):135-143.
4.
CarvalhoAMNovaisFOPaixãoCS, et al. Glyburide, a NLRP3 inhibitor, decreases inflammatory response and is a candidate to reduce pathology in Leishmania braziliensis infection. J Invest Dermatol. 2020;140(1):246-249.e2.
5.
CatapanoMRobinsonDMSchowalterSMcInnisKC.Clinical evaluation and management of calcific tendinopathy: an evidence-based review. J Osteopath Med. 2022;122(3):141-151.
6.
ChenWDengYZhangJTangK.Uniaxial repetitive mechanical overloading induces influx of extracellular calcium and cytoskeleton disruption in human tenocytes. Cell Tissue Res. 2015;359(2):577-587.
7.
CookJLFellerJABonarSFKhanKM.Abnormal tenocyte morphology is more prevalent than collagen disruption in asymptomatic athletes’ patellar tendons. J Orthop Res. 2004;22(2):334-338.
8.
CoxSWEleyBMKiiliMAsikainenATervahartialaTSorsaT.Collagen degradation by interleukin-1beta-stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases. Oral Dis. 2006;12(1):34-40.
9.
Darrieutort-LaffiteCBlanchardFLe GoffB.Calcific tendonitis of the rotator cuff: from formation to resorption. Joint Bone Spine. 2018;85(6):687-692.
10.
De NardoDLatzE. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011;32(8):373-379.
11.
dos SantosRMOliveiraSMSilvaCRHoffmeisterCFerreiraJAssreuyJ.Anti-nociceptive and anti-edematogenic effects of glibenclamide in a model of acute gouty attack in rats. Inflamm Res. 2013;62(6):617-625.
12.
DwivediDKJenaGB.Dimethyl fumarate-mediated Nrf2/ARE pathway activation and glibenclamide-mediated NLRP3 inflammasome cascade inhibition alleviate type II diabetes-associated fatty liver in rats by mitigating oxidative stress and inflammation. J Biochem Mol Toxicol. 2023;37(7):e23357.
13.
FerrySTDahnersLEAfshariHMWeinholdPS.The effects of common anti-inflammatory drugs on the healing rat patellar tendon. Am J Sports Med. 2007;35(8):1326-1333.
14.
HackettLMillarNLLamPMurrellGA.Are the symptoms of calcific tendinitis due to neoinnervation and/or neovascularization?J Bone Joint Surg Am. 2016;98(3):186-192.
15.
HeYHaraHNúñezG.Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41(12):1012-1021.
16.
HermanJLe GoffBDe LimaJ, et al. Pro-inflammatory effects of human apatite crystals extracted from patients suffering from calcific tendinopathy. Arthritis Res Ther. 2021;23(1):131.
17.
HuJJYinZShenWL, et al. Pharmacological regulation of in situ tissue stem cells differentiation for soft tissue calcification treatment. Stem Cells. 2016;34(4):1083-1096.
18.
JiangHHeHChenY, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;214(11):3219-3238.
19.
JiangHXieYLuJ, et al. Pristimerin suppresses AIM2 inflammasome by modulating AIM2-PYCARD/ASC stability via selective autophagy to alleviate tendinopathy. Autophagy. 2024;20(1):76-93.
20.
JiangLLiuTLyuK, et al. Inflammation-related signaling pathways in tendinopathy. Open Life Sci. 2023;18(1):20220729.
21.
JiangSZhaoXChenS, et al. Down-regulating ERK1/2 and SMAD2/3 phosphorylation by physical barrier of celecoxib-loaded electrospun fibrous membranes prevents tendon adhesions. Biomaterials. 2014;35(37):9920-9929.
22.
JinCFrayssinetPPelkerR, et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proc Natl Acad Sci U S A. 2011;108(36):14867-14872.
KelleyNJeltemaDDuanYHeY.The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.
25.
KhareSLucNDorfleutnerAStehlikC.Inflammasomes and their activation. Crit Rev Immunol. 2010;30(5):463-487.
26.
KimMSKimIWLeeSShinSJ.Diagnosis and treatment of calcific tendinitis of the shoulder. Clin Shoulder Elb. 2020;23(4):210-216.
27.
KohGCWeehuizenTABreitbachK, et al. Glyburide reduces bacterial dissemination in a mouse model of melioidosis. PLoS Negl Trop Dis. 2013;7(10):e2500.
28.
LamkanfiMMuellerJLVitariAC, et al. Glyburide inhibits the cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009;187(1):61-70.
29.
LeeHMKimJJKimHJShongMKuBJJoEK.Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62(1):194-204.
30.
LiFMaoDPanXZhangXMiJRuiY.Celecoxib cannot inhibit the progression of initiated traumatic heterotopic ossification. J Shoulder Elbow Surg. 2019;28(12):2379-2385.
31.
LiJWangXYaoZ, et al. NLRP3-dependent crosstalk between pyroptotic macrophage and senescent cell orchestrates trauma-induced heterotopic ossification during aberrant wound healing. Adv Sci (Weinh). 2023;10(19):e2207383.
32.
LiRLaiCLuoH, et al. Animal models of tendon calcification: past, present, and future. Animal Model Exp Med. 2024;7(4):471-483.
33.
LiuLDongYYeM, et al. The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans. J Crohns Colitis. 2017;11(6):737-750.
34.
LiuYRWangJQLiJ.Role of NLRP3 in the pathogenesis and treatment of gout arthritis. Front Immunol. 2023;14:1137822.
35.
LuiPPFuSCChanLSHungLKChanKM.Chondrocyte phenotype and ectopic ossification in collagenase-induced tendon degeneration. J Histochem Cytochem. 2009;57(2):91-100.
36.
ManganMSJOlhavaEJRoushWRSeidelHMGlickGDLatzE. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. 2018;17(8):588-606.
37.
MartinonFMayorATschoppJ.The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-265.
38.
MavrikakisMEDrimisSKontoyannisDARasidakisAMoulopoulouESKontoyannisS.Calcific shoulder periarthritis (tendinitis) in adult onset diabetes mellitus: a controlled study. Ann Rheum Dis. 1989;48(3):211-214.
39.
MerollaGSinghSPaladiniPPorcelliniG.Calcific tendinitis of the rotator cuff: state of the art in diagnosis and treatment. J Orthop Traumatol. 2016;17(1):7-14.
40.
NakajimaKMiyataAKatoSOshimaYTanakaS.Calcific tendinitis of the shoulder induced by an mRNA vaccine for COVID-19: a case report. Mod Rheumatol Case Rep. 2023;7(1):211-214.
41.
OshitaTTobitaMTajimaSMizunoH.Adipose-derived stem cells improve collagenase-induced tendinopathy in a rat model. Am J Sports Med. 2016;44(8):1983-1989.
42.
PanYGHuangMTSekarPHuangDYLinWWHsiehSL.Decoy receptor 3 inhibits monosodium urate-induced NLRP3 inflammasome activation via reduction of reactive oxygen species production and lysosomal rupture. Front Immunol. 2021;12:638676.
43.
ParkSMBaekJHKoYBLeeHJParkKJHaYC.Management of acute calcific tendinitis around the hip joint. Am J Sports Med. 2014;42(11):2659-2665.
44.
Peñin-FranchAGarcía-VidalJAMartínezCM, et al. Galvanic current activates the NLRP3 inflammasome to promote Type I collagen production in tendon. Elife. 2022;11:e73675.
45.
Perucca OrfeiCLovatiABViganòM, et al. Dose-related and time-dependent development of collagenase-induced tendinopathy in rats. PLoS One. 2016;11(8):e0161590.
46.
QiuXWangQHouLZhangCWangQZhaoX.Inhibition of NLRP3 inflammasome by glibenclamide attenuated dopaminergic neurodegeneration and motor deficits in paraquat and maneb-induced mouse Parkinson’s disease model. Toxicol Lett. 2021;349:1-11.
47.
ReesJDMaffulliNCookJ.Management of tendinopathy. Am J Sports Med. 2009;37(9):1855-1867.
48.
SansoneVMaioranoEGalluzzoAPascaleV.Calcific tendinopathy of the shoulder: clinical perspectives into the mechanisms, pathogenesis, and treatment. Orthop Res Rev. 2018;10:63-72.
SuBO’ConnorJP.NSAID therapy effects on healing of bone, tendon, and the enthesis. J Appl Physiol (1985). 2013;115(6):892-899.
51.
ThankamFGRoeschZKDilisioMF, et al. Association of inflammatory responses and ECM disorganization with HMGB1 upregulation and NLRP3 inflammasome activation in the injured rotator cuff tendon. Sci Rep. 2018;8(1):8918.
52.
UhthoffHKLoehrJW.Calcific tendinopathy of the rotator cuff: pathogenesis, diagnosis, and management. J Am Acad Orthop Surg. 1997;5(4):183-191.
53.
UhthoffHKSarkarKMaynardJA.Calcifying tendinitis: a new concept of its pathogenesis. Clin Orthop Relat Res. 1976;(118):164-168.
54.
Vande WalleLLamkanfiM. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2024;23(1):43-66.
55.
VanelliGHussainSNAgugginiG.Glibenclamide, a blocker of ATP-sensitive potassium channels, reverses endotoxin-induced hypotension in pig. Exp Physiol. 1995;80(1):167-170.
56.
WuGSuQLiJ, et al. NAMPT encapsulated by extracellular vesicles from young adipose-derived mesenchymal stem cells treated tendinopathy in a “One-Stone-Two-Birds” manner. J Nanobiotechnol. 2023;21(1):7.
57.
ZahidALiBKombeAJKJinTTaoJ.Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol. 2019;10:2538.
58.
ZhangGLinXZhangSXiuHPanCCuiW.A protective role of glibenclamide in inflammation-associated injury. Mediators Inflamm. 2017;2017:3578702.
59.
ZhangKAsaiSYuBEnomoto-IwamotoM.IL-1β irreversibly inhibits tenogenic differentiation and alters metabolism in injured tendon-derived progenitor cells in vitro. Biochem Biophys Res Commun. 2015;463(4):667-672.
60.
ZhangKWangLZhangS, et al. Celecoxib inhibits the heterotopic ossification in the rat model with Achilles tenotomy. Eur J Orthop Surg Traumatol. 2013;23(2):145-148.
61.
ZhangTDingSWangR.Research progress of mitochondrial mechanism in NLRP3 inflammasome activation and exercise regulation of NLRP3 inflammasome. Int J Mol Sci. 2021;22(19):10866.
